Literature DB >> 15777250

Inflammatory process in Parkinson's disease: role for cytokines.

T Nagatsu1, M Sawada.   

Abstract

Parkinson's disease (PD) is a movement disorder caused by degeneration of the nigrostriatal dopamine (DA) neurons in the substantia nigra pars compacta and the resultant deficiency in the neurotransmitter DA at the nerve terminals in the striatum. We and other investigators found increased levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6, and decreased levels of neurotrophins such as brain-derived neurotrophic factor (BDNF) in the nigrostriatal region of postmortem brains and/or in the ventricular or lumbar cerebrospinal fluid (CSF) from patients with sporadic PD, and in animal models, such as 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)- and 6-hydroxydopamine (6-OHDA)-induced PD. These changes in cytokine and neurotrophin levels may be initiated by activated microglia, which may then promote apoptotic cell death and subsequent phagocytosis of DA neurons. Cytokines as pleiotropic factors, promote signals that either lead to cell death or exert neuroprotective effects. The discovery of toxic changes in trophic microglia by M. Sawada and co-workers is important to this point. Ultimately, microglial cells may regulate cellular changes that cause either harm or benefit by producing cytokines or neurotrophins depending upon the primary cause and the circumstances during the inflammatory process of PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777250     DOI: 10.2174/1381612053381620

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  140 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

Review 2.  A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer.

Authors:  Akira Nakashima; Akira Ota; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2012-05-27       Impact factor: 3.575

Review 3.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

4.  Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.

Authors:  Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

5.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

Review 6.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

7.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

8.  PINK1 and its familial Parkinson's disease-associated mutation regulate brain vascular endothelial inflammation.

Authors:  Wang Yunfu; Liu Guangjian; Zhong Ping; Sun Yanpeng; Fang Xiaoxia; Hu Wei; Yuan Jiang; Hu Jingquan; Wang Songlin; Zhang Hongyan; Liu Yong; Chen Shi
Journal:  J Mol Neurosci       Date:  2014-01-03       Impact factor: 3.444

9.  Genetic variability of inflammatory genes in the Brazilian population.

Authors:  Marcelo dos Santos; Elaine Stur; Lucas Lima Maia; Lidiane Pignaton Agostini; Gabriela Tonini Peterle; Suzanny Oliveira Mendes; Eloiza Helena Tajara; Marcos Brasilino de Carvalho; Iúri Drumond Louro; Adriana Madeira Álvares Silva-Conforti
Journal:  Genet Test Mol Biomarkers       Date:  2013-08-03

Review 10.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.